Clinical Trial Update: Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of MSC-NTF (NurOwn) in participants with early symptomatic amyotrophic lateral sclerosis, with status not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• MSC-NTF (NurOwn)

Snippet

Sponsor: Brainstorm-Cell Therapeutics | Conditions: Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis | Phase 3 | Status: NOT_YET_RECRUITING